⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MLYS News
Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MLYS
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MLYS
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
globenewswire.com
MLYS
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
globenewswire.com
MLYS
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MLYS
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
MLYS
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
globenewswire.com
MLYS
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
MLYS
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
globenewswire.com
MLYS
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
globenewswire.com
MLYS